Proposes a nomenclature change for familial combined hyperlipidemia to hyperapoB to better reflect its underlying pathophysiology of hepatic apolipoprotein B overproduction.
No takes yet. Share an insight, caveat, or question.
May support apoB-centric nomenclature in combined hyperlipidemia; leaves open effects on diagnosis, risk stratification, and management.
Sniderman et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: